Heartflow, Inc. Common Stock

HeartFlow CEO John Farquhar sold 22,562 shares worth ~$626,100 on July 10, 2026, as part of a pre-arranged Rule 10b5-1 trading plan established in September 2025. The sale represents only a 5% reduction in his direct holdings, and he retains 435,373 shares valued at $11.63 million, indicating aligned interests with shareholders. The transaction i...

Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a pr...

Ventripoint Diagnostics announced support for the newly formed Global Congenital Heart Disease Alliance (GCHDA), positioning its AI-powered VMS+ cardiac imaging platform to address a critical global healthcare gap. With 16 million people living with congenital heart disease and over 90% of children in lower-income countries lacking timely care, V...

Stanford University's Board of Trustees completely exited their HeartFlow position by selling 312,234 shares for $8.48 million in Q1 2026. Despite the exit, the article suggests this was a strategic decision to lock in gains rather than a sign of concern, as HeartFlow's business fundamentals remain strong with 40% YoY revenue growth. However, the...

Five companies—VentriPoint Diagnostics, HeartBeam, Heartflow, Hyperfine, and GE Healthcare Technologies—are advancing AI-enabled cardiac diagnostic platforms to address the global heart disease crisis. Recent developments include VentriPoint's partnership with First Light Health for remote Indigenous communities, HeartBeam's collaboration wit...